Abstract: The present invention relates to polyamide compositions and therapies for treating cells and subjects infected with papilloma virus.

Abstract: The field of this invention relates to methods for combining genetic elements such that the activity of one of the elements provides a means for identifying, enriching, selecting for, or enhancing the activity of a second element. The invention also includes specific elements and combinations of elements.

Abstract: An isolated peptide from skin aspartic protease (SASPase) or filaggrin-2 (FLG2), a fragment or homologue thereof, which can modify the three-dimensional shape of a complex formed by interaction between a first amino acid sequence from filaggrin-2 and a second amino acid sequence from SASPase, is described. The isolated peptide is useful as a target for screening for cosmetic or therapeutic active agents with regard to the skin and/or its appendages.

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

Abstract: Reagents and methods for treating dental disease are provided.

Abstract: The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.

Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.

Abstract: The present invention relates to an expression vector containing the major envelope protein P9 of Cystovirus phi12 as a fusion partner, and a process for producing a membrane protein using the same. Particularly, the present invention is directed to an expression vector comprising a major envelope protein P9 gene of Cystovirus phi12, a multicloning site (MCS) for inserting a target membrane protein, and a protease recognition site located between a P9 gene and the MCS.

Abstract: Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells.

Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.

Abstract: The present invention provides recombinant proteins comprising transferrin that is linked to tumstatin or other antiangiogenic protein and methods for producing and using the same. The present invention also provides an expression system, a plasmid, and a cell that is capable of expressing such recombinant proteins and methods for producing and using the same.

Abstract: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.

Abstract: The present disclosure relates generally to anti-rabies antibodies that can bind to and neutralize rabies virus. Antibodies of the present technology are useful alone or in combination with therapies known in the art for the treatment or prevention of rabies infection.

Abstract: The present invention relates to fusion proteins comprising fragments of toxin A and toxin B from Clostridium difficile, such as wherein the first fragment and the second fragment are adjacent to one another and wherein the first repeat portion and the second repeat portion have sequence similarity to one another.

Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.

Abstract: The instant invention relates to the field of protein production and in particular to controlled protein heterogeneity compositions and processes for controlling the heterogeneity of proteins expressed in host cells.

Abstract: To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).

Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.

Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.

Abstract: The present invention relates to ?v?8 antagonists, anti-?v?8 antibodies or immunoconjugates for reducing TGF? activation in an individual. Further provided are compositions comprising one of the ?v?8 antagonists, anti-?v?8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.

Abstract: The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding domains for two different binding sites of LRP6 and compositions and methods of use thereof.

Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.

Abstract: Disclosed herein are method of treating pain using comprising RANK/RANKL antagonists.

Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.

Abstract: The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region 1 such that if at least two of the cysteine residues are not conjugated to another compound a disulphide bond forms between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides a protein that binds to TAG72. The present invention also provides conjugates of the protein and another compound.

Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.

Abstract: The invention provides a method for forming an immobilized agent gradient within a 3-dimensional porous scaffold. A 3-dimensional scaffold formed from a biocompatible material is provided. The surface of the scaffold and/or the agent is activated so as to allow binding of the agent to the scaffold. The activated scaffold is contacted with a solution containing the agent. Contact with the solution is maintained for a sufficient period of time to allow diffusion of the solution through a portion of the scaffold, thereby forming a desired gradient of the agent through the 3-dimensional scaffold.

Abstract: Articles that contain a solid support with a grafted chain extending from the solid support, methods of making these articles, and various uses of the articles are described. More specifically, the grafted chain has a functional group that can react with or interact with target compound. Alternatively, the functional group on the grafted chain can react with a modifying agent to provide another group that can react with or interact with the target compound. The grafted chains are attached to the solid support through a ring-opened azlactone group. The articles can be used to purify the target compound or to separate the target compound from other molecules in a sample.

Abstract: The invention relates to the field of covalently attaching proteins to a substrate, particularly to methods of immobilizing proteins by posttranslationally modifying a cysteine residue of said protein through the addition of functional groups. The invention also relates to biological molecules used in such techniques, including proteins, and detection methods and kits that utilize such immobilized proteins, such as a microdevice or “protein chip”, a high-throughput screening device, and for the microscopy of proteins on a surface.

Abstract: The present invention relates to the field of genetic engineering drugs, particularly to a novel B cell activating factor (BAFF) antagonist and use thereof. The technical problem to be solved by the invention is to find a new and effective selection for the prevention and treatment of autoimmune diseases. The B cell activating factor receptor antagonist is mainly obtained by the fusion of the domain 2 binding BAFF in TACI receptor and the domain binding BAFF in Br3 receptor, and it also can be fused with a Fc segment of IgG1 to obtain a new fusion protein molecule. Experiments indicate that said new fusion protein molecule has the function of BAFF antagonist, which can treat the autoimmune diseases, and supply a new and effective selection for the prevention and treatment of the autoimmune diseases.

Abstract: The present invention relates to a process for washing a polysaccharide-based material which has been subjected to oxidation by at least one oxidizing agent, the said process comprising a first stage of washing with a first densified fluid which is inert with regard to the said oxidizing agent, characterized in that the first stage is followed by a second stage of washing with a washing composition comprising at least one second inert densified fluid and at least one alcohol. The said process according to the invention can additionally comprise a third stage of washing with a third inert densified fluid in order to remove the said alcohol deposited on the said polysaccharide-based material during the said second washing stage. Preferably, the said inert densified fluids are supercritical carbon dioxide.

Abstract: Methods and systems for reducing fouling, including particulate-induced fouling, in a hydrocarbon refining process including the steps of providing a crude hydrocarbon for a refining process and adding an antifouling agent containing a polymer base unit and a polyamine group to the crude hydrocarbon are provided. The antifouling agent can be obtained by converting a vinyl terminated polymer, such as polypropylene or poly(ethylene-co-propylene), to a terminal acyl containing functional group, followed by reacting the terminal acyl containing functional group with a polyamine compound.

Abstract: Disclosed are a modified conjugated diene polymer and a method for preparing the same. Provided are advantageously a modified conjugated diene polymer and a method for preparing the same which provide superior compatibility with an inorganic filler, heat generation, tensile strength and abrasion resistance, low fuel consumption and excellent resistance on wet roads.

Abstract: A solid catalyst component for the (co)polymerization of ?-olefins having general formula (I): ZrnMAlxClMgp (I) wherein: M represents titanium (Ti), vanadium (V), or mixtures thereof; n is a number ranging from 0.01 to 2; x is a number ranging from 0.1 to 4; y is a number ranging from 5 to 53; p is a number ranging from 0 to 15; obtained by means of a process comprising putting at least one zirconium arene in contact with at least one metal compound and, optionally, with at least one compound of magnesium. Said solid catalyst component can be advantageously used as a solid component in a catalyst for the (co)polymerization of ?-olefins. Said catalyst can be advantageously used in a process for the (co)polymerization of ?-olefins.

Abstract: A process for manufacturing terpolymers by polymerization of VDF (vinylidene difluoride), TrFE (trifluoroethylene), and CFE (1-chloro-1-fluoroethylene) or CTFE (chlorotrifluoroethylene) monomers in the presence of a radical polymerization initiator, characterized in that: i) an initial mixture of VDF and of TrFE, free of CFE and of CTFE, is fed into an autoclave, ii) the initiator mixed with water is injected into the autoclave so as to achieve, inside the autoclave, a pressure at least equal to 80 bar, in order to form a suspension of VDF and TrFE monomers in water, iii) a secondary mixture constituted of VDF, TrFE and CFE or CTFE is injected into the autoclave, then iv) as soon as the polymerization reaction starts, said secondary mixture is reinjected continuously into the reactor, so as to maintain therein a constant pressure of at least 80 bar.

Abstract: The present invention relates to a process for preparing a polymer by polymerization of an aqueous solution of one or more monomers in water-in-oil inverse emulsion, in which one or more of the monomers used comprise(s) at least one acid function, the molar percentage of monomers bearing at least one weak acid function relative to all the monomers used being at least 30%, wherein: i) the polymerization is carried out with a concentration of all the monomers in aqueous solution which falls within the range of from 1.3 mmol to 3.6 mmol per gram of aqueous solution, ii) during the polymerization, at most 20% of the acid functions present on the monomers which have at least one acid function are in neutralized form, and also to the polymers which can be obtained by means of such a process.

Abstract: A cyclopentadienyl-substituted Salan catalyst, a catalyst system comprising an activator and the cyclopentadienyl-substituted Salan catalyst, a process comprising contacting one or more olefins with the catalyst system, and polymers produced by the process are disclosed herein.

Abstract: The application relates to polymeric antistatic agents for use in polymer molding compositions, as well as molding compositions containing these antistatic agents, the antistatic agents having good compounding properties and being inexpensive to produce, wherein the antistatic agent is an antistatic agent of the general formula (I) having a polymeric cationic polyelectrolyte constituent produced from diallyldialkylammonium compounds and an anionic counterion A?, in which R1 is uniformly or mutually independently C1-C18 alkyl, A? is an acid anion, and n is a whole number from 10 to 1000.

Abstract: Provided are methods of preparing polymers, such as polyisoprene, polybutadiene, polypiperylene, polycyclohexadiene, poly-?-farnesene, or poly-?-myrcene, using iron complexes. Also provided are novel iron complexes, pre-catalysts, intermediates, and ligands useful in the inventive polymerization system.

Abstract: The present invention provides an optical isomer separating agent and a production method thereof. That is, the present invention provides a one-handed helical poly(diphenylacetylene) compound represented by the following formula (I) [wherein each symbol is as described in the DESCRIPTION], and a production method thereof, an optical isomer separating agent containing the poly(diphenylacetylene) compound, and a packing material for a chiral column, containing the optical isomer separating agent coated on a carrier. Since these have a superior separation ability for a wide variety of compounds, a practical optical resolution method can be provided.

Abstract: A polyolefin has 1) a density in the range of 0.93 to 0.97 g/cm3, 2) a BOCD (Broad Orthogonal Co-monomer Distribution) index defined by a given equation in the range of 1 to 5, and 3) a molecular weight distribution (weight average molecular weight/number average molecular weight) in the range of 4 to 10. A supported hybrid metallocene catalyst comprises a first metallocene compound represented by a first given formulae, a second metallocene compound represented by one of three given formulae, and a support.

Abstract: The present invention provides a system and process for olefin polymerization. The inventive system and process for olefin polymerization facilitate lower operating vacuum pressures in the polymer recovery system by requiring at least two sequential condensing units, wherein at least one of the condensing units operates at significantly lower temperature ranges than the temperature ranges at which the current systems operate.

Abstract: To provide a process for producing a fluoroolefin/vinyl alcohol copolymer with sufficiently high productivity and excellent heat resistance, whereby a quality loss by coloration is prevented, and a fluoroolefin/vinyl alcohol copolymer obtainable by such a process. A process for producing a fluoroolefin/vinyl alcohol copolymer, which comprises a polymerization step of copolymerizing a specific fluoroolefin and a vinyl ether having a hydrogen atom of a hydroxy group of a vinyl alcohol substituted with a protective group which can be deprotected, and a deprotection step of substituting the protective group in polymerized units based on the vinyl ether in the copolymer obtained in the polymerization step, with a hydrogen atom to form a hydroxyl group, and the fluoroolefin/vinyl alcohol copolymer obtainable by such a process.

Abstract: This invention relates to a composition comprising a solvent-based fluoropolymer and its use as a coating additive, and a coating composition comprising the fluoropolymer. The coating composition comprising the solvent-based fluoropolymer provides desirable properties including uniform spreading, and cleanability and increased contact angle to a coated substrate. There is further provided a method of treating a substrate using the coating composition.

Abstract: An optical element including a molded article is provided, the molded article being prepared by molding a polymer prepared by polymerizing a (meth)acrylate compound represented at least by the following general formula (1): wherein a and b are each an integer of 1 or 2; X and Y are each —S— or —O—; R1 and R2 are each an alkyl group having 1 or 2 carbon atoms or a hydrogen atom; and Z1 and Z2 are each an alkyl group having 1 or 2 carbon atoms, having a substituent and represented by the following general formula (2): wherein m is selected from 0 and 1; W is a hydrogen atom or a methyl group; and V is selected from substituents represented by the following: *—O—CnH2n—O—**; *—S—CnH2n—S—**; and *—S—CnH2n—O—**, wherein * represents a bond with an alkyl group; ** represents a bond with a (meth)acryloyl group; n is selected from 2, 3 and 4; and at least one hydrogen atom of —CnH2n— is replaced by a methyl group.

Abstract: A co-polymer includes a polymerization product of: a first monomer: and a second monomer represented by (R1O)(R2O)B-L-X1—PG2 where: L is absent, or is alkylenyl, alkenylenyl, or arylene, wherein the alkylenyl and alkenylenyl are optionally interrupted with one or more oxygen or sulfur atoms; X1 is absent, or is amino, oxo, thio, or phosphino; PG2 is a polymerizable group; R1 and R2 are independently H, alkyl, alkenyl, aryl, C(O)R3, C(O)OR3, C(O)NHR3, or R1 and R2 together with the oxygen atoms to which they are bonded join to form a 5- or 6-membered ring; and R3 is H, alkyl, alkenyl, or aryl, wherein the alkyl and alkenyl are optionally interrupted with one or more oxygen or sulfur atoms.

Abstract: A method for preparing a functionalized polymer, the method comprising providing a reactive polymer, where the reactive polymer includes an oxygen anion, a sulfur anion, or a nitrogen anion, reacting the reactive polymer with carbon disulfide to form a polymer including a dithio carboxyl group, and reacting the polymer including the dithio carboxyl group with a blocking agent.

Abstract: Process for providing a polypropylene composition comprising a branched polypropylene in which a polypropylene with a melt flow rate MFR2 (230° C.) of more than 0.5 g/10 min is reacted with a thermally decomposing free radical-forming agent and optionally with a bifunctionally unsaturated monomer obtaining thereby the branched polypropylene, wherein the polypropylene composition has a F30 melt strength of more than 20.0 cN and a V30 melt extensibility of more than 200 mm/s.